Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease - Wikidata - awgldk - TriplyDB

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

http://www.wikidata.org/entity/Q24635129

about

Intrabody and Parkinson's disease Association of Huntington's disease and schizophrenia-like psychosis in a Huntington's disease pedigree.The P42 peptide and Peptide-based therapies for Huntington's disease Engineering humoral immunity as prophylaxis or therapy Mechanisms of RNA-induced toxicity in CAG repeat disorders Intrabodies as neuroprotective therapeutics Engineered antibodies Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts.Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.A protein-tagging system for signal amplification in gene expression and fluorescence imaging.Antigen-independent selection of stable intracellular single-chain antibodies.Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein Efficient isolation of soluble intracellular single-chain antibodies using the twin-arginine translocation machinery.Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.An engineered viral protease exhibiting substrate specificity for a polyglutamine stretch prevents polyglutamine-induced neuronal cell death.Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity Detecting morphologically distinct oligomeric forms of alpha-synuclein.Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Gene therapy in mouse models of huntington disease.Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model Development of novel therapies for Huntington's disease: hope and challenge.The emerging role of the first 17 amino acids of huntingtin in Huntington's disease Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin

P2860

Q24653530-FBE010EA-AC13-4391-84DB-2E0D538D1ABF Q25255735-2979988A-36C1-4391-878A-88F8D560CF74 Q26764930-A4C3ED84-6116-444A-B8B2-91B0679B2DD9 Q26800101-2285F775-9A3C-49EB-8952-F36371FFB4AF Q26860030-9F2C971A-F375-4154-B1CA-330D69E4DF93 Q27003896-044C4CEF-C79C-49D9-87E4-B4EDD8BC12CF Q28201899-26BE1DCD-2549-49E2-8476-1E0BC4CB5FDC Q30441792-1753C005-D4B0-482B-9838-895E272FCD87 Q30490726-F6DF4E24-3A87-48FD-95B9-BD58E3F358EF Q30493159-A413320F-B988-4938-8B0F-9BA6AD7FBAD3 Q30604320-5947B299-6E38-43E4-A832-F3474FA66E2E Q30772110-D0CCE548-34B0-4C04-8ACD-80500358627C Q30832090-A461E639-6009-4AA5-9560-D9B13E9CFC01 Q30851967-1916BD98-13BA-4CD5-86AF-C4FC5BA59CCD Q30980477-F38EDBC4-C553-4288-B365-4870198FC7A3 Q31028322-57574501-0C42-4494-8D19-E2CCF8A50033 Q31105703-13C55B05-D58D-4713-9720-6AC97FFDE6D8 Q33280345-4C38809F-77B4-42A5-9162-C5E655205426 Q33317678-079B4255-5752-44A3-8CDB-9B24249D4A0B Q33399653-D0B83F2A-86B2-4D56-A6CD-0C58D1861CCB Q33459255-7198A47B-B224-4FE3-A000-5E480567EF89 Q33572338-EB19D2F2-315F-4199-98EF-97A507ECC024 Q33580733-3C60197D-B4BE-4B44-8DB8-4A8FE3A55713 Q33843281-84EFD843-76F8-43E7-B448-42EF574B5EAD Q33894812-E1D8C046-242C-492E-A51B-18E3D5FAA865 Q33914222-A05B06A0-8B36-4998-87A7-C11CEBFA00C3 Q34077018-24C39508-0503-418A-ACEB-E8CB47903282 Q34117333-1E5837D4-E2AE-466C-8C14-9DC9805C87B7 Q34313192-1A302A77-EE4D-48FD-B574-A5BD42E63D3E Q34385892-F5A57C3B-501A-4D3B-B223-D6D0FB16AA18 Q35090208-42CB7DDD-B4BB-4681-BD0E-1817FA226FBE Q35095142-3C4C8D76-8DB5-4085-BEF5-40A695C6463B Q35244160-7D472F01-BB7A-425C-AA62-12D761A1F863 Q35708355-866E9651-ECF0-4643-B1EF-52261929B758 Q35748307-11FC3039-7E8D-4B13-A283-3637C111AA22 Q36016932-EA4FBE5F-63DF-4A27-BD06-6C9BB2722124 Q36110838-25CF5C22-98FA-4A42-BFAC-EB551955A795 Q36142398-345D71EA-2E4B-4859-B5E8-DB646BED6D5A Q36185625-1B5C5DE4-4544-409E-9EF6-69F4D42E3FE9 Q36677547-BBEC5A15-BB2C-4381-B652-78B485CD4099

P2860

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

http://www.wikidata.org/entity/Q24635129

description

2001 nî lūn-bûn

@nan

2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

name

Human single-chain Fv intrabod ...... models of Huntington's disease

@ast

Human single-chain Fv intrabod ...... models of Huntington's disease

@en

Human single-chain Fv intrabod ...... models of Huntington's disease

@nl

type

label

Human single-chain Fv intrabod ...... models of Huntington's disease

@ast

Human single-chain Fv intrabod ...... models of Huntington's disease

@en

Human single-chain Fv intrabod ...... models of Huntington's disease

@nl

prefLabel

Human single-chain Fv intrabod ...... models of Huntington's disease

@ast

Human single-chain Fv intrabod ...... models of Huntington's disease

@en

Human single-chain Fv intrabod ...... models of Huntington's disease

@nl

P1433

Q24635129-D808A2DA-8555-4952-8BF8-3E1A2A75D839

P1476

Q24635129-1CCDA216-9299-40FB-8057-04FF2158E1B6

P2093

Q24635129-44EE7F74-B629-4372-8B5F-A40E9FCDFC52

Q24635129-5AC1B959-8F08-44C8-AA2D-7D366D994139

Q24635129-78C4AC9D-01C4-479F-B412-B4492BB0A5C0

Q24635129-8C66BDA7-7506-4ADE-8A60-3D7112DDD013

Q24635129-925D1B3F-6103-436C-A149-B17DA1F9A6B8

Q24635129-B91E615B-3A1C-4BA0-91A1-9A7B47EB65B3

Q24635129-C2C4EBBB-64AF-4CA8-A25C-4B7F0ACA0E99

Q24635129-C74B4708-E2F6-4257-BD44-EE5EB624A89A

P2860

Q24635129-11220D05-EBF1-4B55-93E4-2164898F6119

Q24635129-1B9C2E13-3B10-4A68-844E-231143E207DF

Q24635129-3D944092-366B-45E2-BEF0-A33CFAF1C8E5

Q24635129-46BE6E78-19BA-4A52-BB83-D2A3DC7399F7

Q24635129-4EE14367-D165-47B5-AF28-A0B6AE5139DC

Q24635129-5DF0A719-C005-40EE-BF8F-FBDDF099138E

Q24635129-5FCBE1E4-772B-49A1-B35C-8626C473AE9E

Q24635129-62539425-A1B3-44FF-BE67-B8C1F0DC2301

Q24635129-65421494-CADE-4F10-B5F5-442BE7D15E4D

Q24635129-6DC1CFD5-72A5-476F-ADEA-0268941BC40F

P304

Q24635129-1385E523-5725-4A58-876E-820082C116A4

P31

Q24635129-89B68B60-9FDA-440E-9150-BE632FCF845E

P3181

Q24635129-65B3DF3A-EE74-4C4F-8B9C-4403625DFA8E

P356

Q24635129-B1F69A3A-3A51-4D1E-8D6F-F366F2CF81BC

P407

Q24635129-5CDDBAA6-7AE9-49B6-86F4-55B7C2520B02

P433

Q24635129-D0CD9AAF-5947-4470-9CFE-4E0BC6D0FDA5

P478

Q24635129-65D8171D-157C-491A-9BC2-68D82DD3F512

P577

Q24635129-0209ADB0-5493-4DD1-83B3-6F38E6EB5D06

P5875

Q24635129-B0F05638-F942-44FE-9D98-7F7E634A8EDD

P698

Q24635129-C50C17CF-62EE-4352-9968-4F21F8030A8C

P921

Q24635129-AB46A151-56D9-4630-8655-6AA46BA9A367

P932

Q24635129-B9D5D89E-ACFD-4FB3-AB68-C83109B1336C

P3181

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Human single-chain Fv intrabod ...... models of Huntington's disease

@en

P2093

A Kazantsev

http://www.w3.org/2001/XMLSchema#string

A Messer

http://www.w3.org/2001/XMLSchema#string

D E Housman

http://www.w3.org/2001/XMLSchema#string

J M Lecerf

http://www.w3.org/2001/XMLSchema#string

J S Huston

http://www.w3.org/2001/XMLSchema#string

P Amersdorfer

http://www.w3.org/2001/XMLSchema#string

Q Zhu

http://www.w3.org/2001/XMLSchema#string

T L Shirley

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Functional domains and upstream activation properties of cloned human TATA binding protein

Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue

Inactivation of the mouse Huntington's disease gene homolog Hdh

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

P304

4764-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2635967

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.071058398

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12038390

http://www.w3.org/2001/XMLSchema#string

P698

11296304

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

31908

http://www.w3.org/2001/XMLSchema#string